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SUMMARY
Most cases of adult myeloid neoplasms are routinely assumed to be sporadic. Here, we describe an adult
familial acute myeloid leukemia (AML) syndrome caused by germline mutations in the DEAD/H-box helicase
gene DDX41. DDX41 was also found to be affected by somatic mutations in sporadic cases of myeloid
neoplasms as well as in a biallelic fashion in 50% of patients with germline DDX41mutations. Moreover, cor-
responding deletions on 5q35.3 present in 6% of cases led to haploinsufficient DDX41 expression. DDX41
lesions caused altered pre-mRNA splicing and RNA processing. DDX41 is exemplary of other RNA helicase
genes also affected by somatic mutations, suggesting that they constitute a family of tumor suppressor
genes.
INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group
of myeloid neoplasms characterized by cytopenia, morphologic
dysplasia, cytogenetic abnormalities, and propensity to prog-
ress to secondary acute myeloid leukemia (sAML). Although
closely related to primary forms of acute myeloid leukemia
(AML), MDS predominantly affects the elderly. Next-generation
Significance
Wehave identified a familial AML syndrome characterized by long latency and germlinemutations in the gene coding for the
DEAD-Box helicase DDX41 located on chr. 5q35. Recurrent somatic DDX41 mutations were identified in myeloid neo-
plasms; approximately 50% of cases in patients with germline mutations harbored somatic point mutations in the other
allele. In addition to mutations,DDX41 locus was deleted in 26% of MDS cases with del(5q) and resulted in haploinsufficient
expression.DDX41 defects led to loss of tumor suppressor function due to altered pre-mRNA splicing and RNA processing.
Somatic mutations were also found in other RNA helicase genes, suggesting that they constitute a family of tumor suppres-
sor genes in myeloid neoplasms.
658 Cancer Cell 27, 658–670, May 11, 2015 ª2015 Elsevier Inc.
sequencing (NGS) in MDS led to the discovery of relevant
somatic mutations and their combinations (Patel et al., 2012;
Walter et al., 2013). The spectrum of affected genes overlaps
with those seen in AML and the closely relatedmyeloproliferative
neoplasm (MPN) and myelodysplastic (MDS) syndromes.
Familial MDS has been rarely reported, usually in the context
of early-onset disease and germline mutations. Patients with
germline RUNX1 mutations present with thrombocytopenia
and frequent progression toward MDS/AML (Owen et al.,
2008). Similarly, germline CEBPA and GATA2 mutations have
been associated with AML and early-onset MDS/AML (Owen
et al., 2008; Hahn et al., 2011). Among patients with typical
MDS, late presentation makes it difficult to distinguish hereditary
factors from aging and cumulative environmental exposures
(Pfeilsto¨cker et al., 2007; Sekeres, 2010). Nevertheless, in rare
cases, a strong family history may suggest a genetic predisposi-
tion, illuminating the seemingly sporadic cases.
While investigating genetic causes of AML families affected by
myeloid neoplasms, we identified germline mutations in a DEAD/
H-box helicase gene that induced late-onset MDS/AML with a
predisposition to acquisition of somatic DEAD/H-box mutations.
RESULTS
Identification of Myeloid Leukemias with Mutant
Familial DDX41Mutations
In the index family, father, son, and paternal grandmother were
affected by de novo AML, while sAML from antecedent MDS
(refractory anemia with excess blasts [RAEB]) was diagnosed
in a daughter. Age at disease onset ranged from 44 to 70 years.
Using whole exome sequencing (WES), we found a recurrent
germline mutation of DDX41 (c.419insGATG, p.D140fs) in the
father, son, and daughter. The prevalence of this germline
minor allele in the general population is 1/12,518 (National Heart,
Lung, and Blood Institute [NHLBI] GO Exome Sequencing
Project [ESP]; https://esp.gs.washington.edu/drupal/). This
alteration was not found in 200 internal controls. Subsequent
analysis of acquired sequence alterations also revealed the
concomitant presence of a canonical somatic mutation of
DDX41 (c.G1574A, p.R525H) in the father and son (Figure 1A;
Figure S1A). Germline and somatic DDX41 mutations were
distinguished by analysis of buccal DNA in patients. In two
other sons (55 and 56 years), the heterozygous mutation
(c.419insGATG, p.D140fs) was detected with no apparent dis-
ease, but both of them have developed slight monocytosis.
Blood smears from both showed the presence of immature
monocytes (Figure S1B). They were younger than most of the
patients with germline DDX41 mutations (Figure S1C). The ca-
nonical somatic mutation of DDX41 (c.G1574A, p.R525H) was
not detected. In a second family, identical twin brothers devel-
oped MDS (refractory cytopenia with multilineage dysplasia
[RCMD]), and AML was observed in their father. Both brothers
were successfully treated with lenalidomide for transfusion-
dependent anemia. Both twins showed a germline DDX41
variant (c.T1187C; p.I396T; Figure 1B; Figure S1D). As in the in-
dex family, they also showed the somatic DDX41 (p.R525H)
mutation. The germline alteration p.I396T was not found in 200
internal controls or in available databases (1,092 controls;
http://www.1000genomes.org/ and ESP). In the third family,
we identified a 67-year-old male patient (case 6) diagnosed
with MDS-RAEB-1 who harbored both canonical germline and
somatic DDX41 mutations p.D140fs and p.R525H, respectively.
His brother also died from AML at the age of 58 years (Figure 1C;
Figure S1E).
In another leukemia family (Figure S2A), a 73-year-old male
patient (case 7) was diagnosed with secondary AML, whereas
his nephew (case 8) presented with AML at the age of 56. Both
patients harbored the canonical germline DDX41 mutation.
Paternal cousins of the index case were also afflicted by AML
at the ages of 79 and 89, but they declined genetic testing.
Through further search (Table 1), we identified an additional three
cases with advanced MDS and a strong family history of MDS/
AML (families 5–7) who harbored DDX41 alterations; two of
them showed both germline and somatic mutations of DDX41
(Figure S2B).
DDX41 and Other Helicase Defects in Myeloid
Neoplasms
In addition to cases with a strong family history of MDS/AML
(families 1–7), a cohort of 1,034 patients with MDS and sAML
was subjected to a targeted screening by NGS (Table S1). We
identified six additional patients with the germline c.419insGATG
variant (cases 12 and 14–18; Figure S2C) and two patients
with two different germline mutations of DDX41 (case 13,
c.156_157insA and p.Q52fs, and case 19, c.G465A and
p.M155I). The former alteration was not found in public data-
bases, but the prevalence of the latter alteration in the general
population is 5/13,006 (ESP). In total, DDX41 mutations were
identified in 27 out of 1,045 patients with myeloid neoplasms
(Table 1). Simultaneously, we identified a total of 17 cases
with somatic DDX41 mutations: 13 with recurrent missense
mutations (p.R525H), 3 with non-recurrent missense muta-
tions (c.C674A, p.A225D; c.C962T, p.P321L; and c.G739A,
p.E247K), and 1 with splice-site mutation (e11+1). The occur-
rence of somatic DDX41 mutations was closely linked to the
presence of DDX41 germline mutations. Approximately 50% of
patients with germline DDX41 mutations also acquired the
somatic mutation, while 0.8% patients with wild-type (WT)
DDX41 acquired a somatic DDX41 mutation (p < 0.001; Figures
S2D and S2E). The additional somatic mutations were always
acquired in the remaining WT allele (Figure S2F).
Somatic mutations ofDDX41 affected the ATP binding domain
(Figure 2A). Because germline mutations were predominantly
out-of-frame insertions and they coincided with somatic
DDX41mutations suggested that defects of this gene may result
in a loss of function. Consequently, deletion andmutations of this
gene may be functionally equivalent. Deletions of the long arm of
chr.5 involving the DDX41 locus (5q35.3) were present in 6% of
all cases and 26% of the del(5q) cases (Figure 2A; Figure S3A)
and resulted in decreased DDX41mRNA levels (p = 0.0004; Fig-
ure 2B). Of note, the inactivating germline c.419insGATG muta-
tion was not found among patients with del(5q35.3). Germline
DDX41 mutations, per definition, can be considered founder
lesions. When we analyzed the clonal architecture of somatic
DDX41 mutations, we observed an average variant allelic fre-
quency (VAF) of 25 ± 10%. VAF in other important genes showed
larger (SF3B1, TET2) and smaller (SMC3, NPM1) clone sizes
(Figures 2C and 2D) in the corresponding cases. Whereas
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Figure 1. Germline and Somatic Mutations of Three Families with History of MDS and Leukemia
(A–C) Pedigrees of family 1 (A), family 2 (B), and family 3 (C) (upper panels). Age of diagnosis and detected DDX41mutations are indicated. Lower panels show
sequencing reads from WES with frequencies of detected mutations in bone marrow (BM) and germline samples. Confirmation of germline and somatic DDX41
mutations by Sanger sequencing is exemplarily shown for family 2 (B). Arrows and bars indicate the specific nucleotide and predicted codon, respectively. Case
number is annotated according to Table 1. Asymptomatic/presymptomatic carrier is clinically unaffected at this time but could later exhibit symptoms (Bennett
et al., 2008). See also Figure S1.
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somatic DDX41 mutations are ancestral in some patients, they
also appear to be present as subclones in others (Figure 2E).
Somatic mutations of DDX41 occur but are rare in non-hema-
tologic malignancies (http://www.sanger.ac.uk). We observed
15 somatic mutations (n = 342) in genes encoding other mem-
bers of the DEAD/H-box RNA helicase family. Defects of the
helicase family were mutually exclusive (Figure S3B). We
also identified two rare germline events: DHX29 c.G1627A
(p.V543M) and c.G1561A (p.E521K), not found in ESP. In addi-
tion, deletions of DDX4 (5q11.2) and DHX58 (17q21.2) loci
were identified in 14 and 13 cases, respectively (data not shown).
Clinical Aspects of DDX41Mutations
DDX41 mutations and deletions occurred more frequently in
patients with advanced MDS (19% in advanced MDS versus
6% in low-risk MDS; p = 0.02; Figures 3A and 3B) and with
AML (12% of primary, n = 302; and 13% of secondary AML,
n = 154). Overall, patients with either DDX41 mutations or
deletions had inferior overall survival (OS) (Figure 3C). Similar
phenotypic associations (Figure 3B) (Boultwood et al., 2007)
and effects on OS (Figure 3D) were observed in cases with
decreased DDX41 expression.
We noted that both twins (family 2) with germline and so-
matic DDX41 mutations responded well to lenalidomide,
despite the absence of del(5q) (List et al., 2006), which led
us to investigate the association between somatic DDX41
mutations and response to lenalidomide within a cohort of
111 patients with and without del(5q) treated with this drug
(Table S2). Patients with DDX41 mutations responded better
to lenalidomide treatment (Figure 3E). Furthermore, 19 of 111
cases were also analyzed for DDX41 expression by TaqMan
PCR (Figures 3F and 3G; Table S3). When we compared the
expression of DDX41 between responders (n = 9) and re-
fractory cases (n = 10), responders showed significantly
lower DDX41 mRNA levels (Figure 3F). Patients with either
low expression or DDX41 mutations (7/9) showed better
response rate (78% versus 20%) compared to others
(Figure 3G).
Germline and somatic DDX41 mutations were associated
with normal karyotype disease (70% versus 47% without
DDX41 mutations; p = 0.0045; Table S4). Approximately 50%
of DDX41 mutant cases did not harbor additional mutations
(13 cases were sequenced by WES, whereas 14 cases were
sequenced by deep-targeted re-sequencing). Nine of 11 cases
Table 1. Characteristics of DDX41 Mutants
Family Cases Age Sex Disease Germline Event DDX41 Somatic Mutation Cytogenetics
Family 1 1 70 M pAML P.D140fs P.R525H normal
Family 1 2 44 F sAML P.D140fs no normal
Family 1 3 45 M pAML P.D140fs P.R525H normal
Family 2 4 64 M RCMD P.I396T P.R525H normal
Family 2 5 66 M RCMD P.I396T P.R525H normal
Family 3 6 67 M RAEB-1 P.D140fs P.R525H normal
Family 4 7 73 M sAML P.D140fs NA 46,XY,r(7)(p11q21)[7]/46,XY[8]
Family 4 8 56 M pAML P.D140fs NA 46,XY,del(20)(q11.21q13.33)[4]/46,XY[14]
Family 5 9 72 M RAEB-1 P.D140fs P.R525H normal
Family 6 10 62 M RAEB-2 P.D140fs no normal
Family 7 11 65 M RAEB-1 P.F183I P.R525H normal
12 85 M sAML P.D140fs P.R525H 47,XY,+8[2]/46,XY[18]
13 74 M sAML P.Q52fs P.A225D 44,XY,del(7)(q22),-16,-17,-18,-20,+2mar[2]/
45,idem,+8[10]/46,XY[8]
14 58 M RAEB-1 P.D140fs no normal
15 69 M CMML-1 P.D140fs no NA
16 88 M RAEB-1 P.D140fs no normal
17 71 M pAML P.D140fs no normal
18 68 M sAML P.D140fs no 46,XY,-7,+mar[2]/46,XY[19]
19 78 M RAEB-1 P.M155I no 46,XY,del(20)(q11.2)[17]
20 64 M 5q-syndrome no P.R525H 46,XY,del(5)(q12q33)[6]
21 68 M RAEB-2 no P.R525H normal
22 63 M pAML no P.R525H normal
23 66 M RCMD no P.R525H normal
24 46 M RAEB-2 no P.R525H normal
25 78 M RCMD no P.P321L normal
26 70 F 5q-syndrome no P.E247K 46,XX,del(5)(q13q33)[20]
27 68 M pAML no splice site (e11+1) normal
See also Figure S2 and Table S1.
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Figure 2. DDX41 Gene Structure and Clonal Architecture in DDX41 Mutants
(A)DDX41 is located at the distal end of chromosome 5q, 5q35.3, and encodes a protein that contains three known domains and ATP binding sites, as illustrated.
The pink bars visualize deletions of chromosome 5q in our MDS cohort that include theDDX41 locus. The red triangles indicate DDX41mutations in patients with
hematological malignancies from our cohort and TCGA. Red circles indicate the identified germline mutations of DDX41 (p.Q52fs, p.D140fs, p.M155I, and
p.I396T). The p.R525H mutation was detected in 13 out of 1,045 cases. Purple triangles show DDX41 mutations in non-hematological malignancies. Sanger
sequencing confirming recurrent germline mutation (p.D140fs; left) and somatic mutation (p.R525H; right) of DDX41 are shown.
(B) DDX41mRNA expression was analyzed by real-time RT-PCR in cases with deleted DDX41 locus compared with cases without deletion. Boxes represent 25–
75 percentiles. A line inside a box represents the median. Whiskers indicate maximum and minimum values.
(legend continued on next page)
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with familial MDS/AML presented with normal karyotype and
lacked typical AML-associated mutations. In addition to the
predisposition for somatic DDX41 mutations, germline DDX41
mutations were associated with several other somatic muta-
tions; among the 62 most frequently mutated genes, DDX41 le-
sions coincided with TP53, RUNX1, and LUC7L2 mutations
(Figure S4).
(C) For cases with DDX41 mutations, variant allelic frequencies (VAFs) of DDX41 mutations (germline and somatic) and concomitant mutations of other genes
(somatic) are shown. Mean values of VAFs were compared between somatic DDX41 and concomitant mutations (mean ± SD: 25 ± 10% and 29 ± 14%,
respectively; p > 0.05).
(D) For cases in the whole examined cohort, VAFs of DDX41 mutations (mean ± SD: 25 ± 10%) were compared to those of other genes affected by somatic
mutations in myeloid neoplasms, including patients with DDX41 mutations. VAF is indicated as mean ± SD. *p = 0.004.
(E) Clonal architecture of eight cases with DDX41 mutations. The percentages represent allelic frequencies with 50% set as the largest circle; case 1: 50% of
DDX41-D140fs (germline mutation), 25% of SMAD1-T4I, and 21% of DDX41-R525H; case 3: 50% of DDX41-D140fs (germline mutation) and 12% of DDX41-
R525H; case 4: 50% of DDX41-I396T (germline mutation), 42% of DDX41-R525H, 15% of PHF6-C20fs, and 14% of DNMT3A-C394R; case5: 50% of DDX41-
I396T (germline mutation), 46% of JAK2-V617F, and 37% of DDX41-R525H; case 6: 50% of DDX41-D140fs (germline mutation), 37% of CDH26-P304S, 22% of
TP53-S94X, and 20% of DDX41-R525H; case 9: 50% of DDX41-D140fs (germline mutation), 30% of RUNX1-P68R, and 25% of DDX41-R525H; case 12: 50% of
DDX41-D140fs (germlinemutation) and 11%ofDDX41-R525H; and case 23: 36%ofDDX41-R525H, 34.8%of TP53-D149G, and 11.1%ofRUNX1-G108D. (Case
number is annotated according to Table 1.)
See also Figure S3.
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Figure 3. Clinical Impact of DDX41 Defi-
ciency in Myeloid Neoplasms
(A) Patients with somatic DDX41 defects (muta-
tions and deletions) in different types of myeloid
neoplasms. Indicated is the percentage of patients
of each cohort with DDX41 deletions and muta-
tions. The absolute number of patients with alter-
ations is shown on the top of each bar.
(B) DDX41 mRNA levels in MDS patients with
different subtypes. Reduced DDX41 expression
was also demonstrated in various categories. Bars
represent mean value.
(C) Overall survival analysis in patients with DDX41
mutations or deletions compared with WT cases
(HR = 3.5; 95% CI = 2.0–5.9; and p < 0.0001).
(D) Overall survival analysis in patients with low
DDX41mRNA expression compared with patients
with higher expression (HR = 1.6; 95% CI = 1.0–
2.2; and p = 0.029). Cases with high and low
DDX41 expression were dichotomized by the
mean of relative mRNA transcription levels
(mean = 3.85 relative mRNA expression).
(E) Response rate to lenalidomide in patients with
DDX41mutants (n = 8/8) compared with WT cases
(n = 55/103). p = 0.01.
(F) DDX41 mRNA expression in lenalidomide re-
sponders (n = 9) compared with non-responders
(n = 10). Single square represents individual
patients. Horizontal line indicates mean value.
p = 0.048.
(G) Response rate to lenalidomide treatment of
patients with DDX41 mutations and/or low
DDX41 expression (n = 7/9) compared with others
(n = 2/10).
See also Figure S4 and Tables S2–S4.
Functional Consequences of
DDX41 Lesions
DDX41 is expressed in CD14+, CD33+,
and CD34+ myeloid cells (Figures S5A
andS5B), consistent with a function in he-
matopoiesis. The DDX41 protein is highly
conserved among species. The existing structure of the partial
helicase domain of human DDX41 (PDB ID: 2P6N) and the struc-
ture of Drosophila Vasa (PDB ID: 2DB3) were used to generate a
structural model (Figure S5C). Germline DDX41 frameshift muta-
tions lead to a loss of function. Somatic DDX41 mutations are
possibly hypomorphic, based on the location in the ATP binding
domain. To model consequences of DDX41 deficiency, we used
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lentiviral shRNA delivery to knock downDDX41 in K562 cells and
observed enhanced proliferation compared to mock transduced
cells (Figures 4A and 4B). Similarly, CD34+ hematopoietic pro-
genitor cells transduced with shRNA against DDX41 showed
significantly enhanced colony formation (Figure 4C). When serial
replating assays were used to assess the effects of DDX41 on
retention of clonogenic capacity (Sontakke et al., 2014; He
et al., 2011), knockdown cells showed significantly increased re-
plating efficiency consistent with retained clonogenic properties
(Figure 4C). Anti-proliferative properties ofDDX41were also sug-
gested by the results of cultures performed in the presence of
various growth conditions. When we cultured CD34+ cells with
knockdown of DDX41, decreased levels of DDX41 resulted in a
higher sensitivity to growth factor stimuli compared to control
(Figures 4D and 4E). As an experiment for the tumor suppressor
functions of DDX41, forced expression in U937 cells, which ex-
press low levels of endogenous DDX41, inhibited growth (Fig-
ure 4F). In primary MDS, we applied similar ectopic expression
experiments for haploinsufficient DDX41 expression due to
del(5q). We selected one representative sAML case in which
deletion with haploinsufficient DDX41 expression was confirmed
by SNP-A and quantitative RT-PCR. Forced expression of
DDX41 in these DDX41-defective primary cells reduced colony
formation (Figure S5D). These results further suggested that
loss of DDX41 expression is associated with enhanced prolifer-
ative capacity in myeloid neoplasms. To validate the results of
in vitro studies, we performed xenograft experiments with cell
lines in which DDX41 was knocked down and demonstrated
accelerated tumor growth compared to mock transduced cells
(Figure 4G).
In addition to increased proliferative capacity, we evaluated
anti-differentiation and anti-apoptotic potential due to reduction
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B C
Figure 4. Biological Consequences in
DDX41-Deficient Cells
(A) Expression level ofDDX41 in leukemic cell lines
K562 and U937 and primary CD34+ cells as
determined by normalization to GAPDH upon
knockdown or overexpression of DDX41.
(B) Growth curves of K562 leukemic cells trans-
duced with DDX41 knockdown construct (sh-
DDX41) or mock transduced. Doubling time of
mock versus sh-DDX41 = 29 hr versus 24 hr.
(C) Colony-forming assay comparing DDX41-
deficient with control primary CD34+ cells.
Numbers of plating are indicated. BFU-E, burst
forming unit-erythroid; CFU-GM, colony-forming
unit-granulocyte/macrophage.
(D) Percentage of CFU-GM colonies derived from
plating of DDX41-deficient primary CD34+ cells in
the absence or presence of different concentra-
tions of GM-CSF in methylcellulose semisolid
medium.
(E) Percentage of CFU-GM colonies derived from
plating of DDX41-deficient CD34+ primary cells
with various concentrations of FBS.
(F) Growth curves of U937 cells after lentiviral
infection with a DDX41 expression construct
compared to mock infected control cells.
Doubling time of mock versus DDX41 = 31 hr
versus 36 hr.
(G) K562 cells with decreased DDX41 expression
were injected into the left flank, and those with
mock transduction were injected into the right
flank of NSG mice. n = 3 for each experiment. A
representative image and quantification of tumor
volume are shown. Three series of independent
experiments were performed. Scale bar, 1 inch.
(H) Hemoglobin detection of K562 cells with
decreased DDX41 expression compared to those
with mock transduction before and after exposure
to apigetrin. Hemoglobin was measured by
benzidine staining.
(I) Percentage of small cell population (mature
erythroid cells) as detected by flow cytometry in
DDX41 knockdown K562 cells compared with
control cells after exposure to apigetrin.
Each bar/value represents the mean ± SEM of
three independent experiments performed in
duplicate unless stated otherwise. *p < 0.05. See
also Figure S5.
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of DDX41 function. DDX41 knockdown in K562 cells slightly
impaired apigetrin-induced erythroid differentiation (Figures
4H, 4I, S5E, and S5F). As a rescue experiment, flow cytometry
analysis showed higher expression of the CD11b and CD14 dif-
ferentiation marker in U937 cells with forced expression of
DDX41 (Figure S5G). In addition, up-modulation of DDX41
reversed the relative apoptotic resistance of U937 cells (Fig-
ure S5G). Using murine linsca 1+c-kit+ (LSK) cell model
(Oakley et al., 2012), we also confirmed higher levels of c-kit
and lower expression of Gr-1 upon DDX41 knockdown, illus-
trating defective differentiation in DDX41-deficient cells
(Figure S5H).
Defective function of DDX41 may constitute a vulnerability of
affected cells and provides a rationale for synthetic lethal
intervention. When we tested a previously described helicase
inhibitor, compound 8 (C14H15N3O) (Radi et al., 2012) in the len-
tiviral-induced knockdown model in vitro, in the range of 1 to
10 mM, knockdown cells displayed increased susceptibility to
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Figure 5. Protein Interactions of DDX41 and
Splicing Factors
(A) DDX41 interactions with spliceosomal protein
complexes are indicated. Spliceosomal proteins
that co-immunoprecipitated with DDX41 were
organized in colored functional protein complexes
based on Ingenuity pathway analysis and pub-
lished data (Hegele et al., 2012). Individual protein
enrichment was presented as total spectral
counts and displayed by different circle size.
Increased circle size indicates higher number of
total spectra counts for the protein. Total spectral
count is a semiquantitative method to predict
abundance of a specific protein and is not used to
compare with abundance of other proteins. Un-
filled double-ring symbols indicate proteins that
were not identified in DDX41 co-immunoprecipi-
tation experiments but that have been linked to the
spliceosome.
(B) Summary of cataloging and quantification of
protein interactions with WT and mutant DDX41.
Protein names and their associated spliceoso-
mal complex are shown on top of bars. Protein
abundance was normalized to DDX41 and pre-
sented as ratio of mutant to WT in log2 scale.
Light purple shading indicates no significant
difference in protein interaction between WT
and mutant DDX41 (log2 scale between 0.5
and 0.5). ± SD was calculated based on the
three strongest peak intensities used in the
calculation.
See also Figure S6and Table S5.
C14H15N3O inhibition compared to mock
transduced controls (Figures S5I–S5K).
The precise function of DDX41 is not
yet known, but an involvement of RNA
helicases in RNA splicing has been pro-
posed (Cordin et al., 2012; Staley and
Guthrie, 1998; Schwer and Meszaros,
2000). Mutations of other spliceosomal
proteins are common in myeloid neo-
plasms (Maciejewski and Padgett, 2012)
and were mutually exclusive with DDX41mutations in our cohort
(Figure S6A). To further elucidate a role for DDX41 in the spliceo-
some, we expressed an epitope-tagged version of WT DDX41 in
HEK293 cells and performed a mass spectrometry analysis of
proteins associated with DDX41 in an antibody pull-down fol-
lowed by peptide sequencing. Spliceosomal proteins consti-
tuted the top functional group associated with DDX41 (Fig-
ure S6B), and many of them interact with DDX41 (Figure 5A;
Table S5). Among many, PRPF8 and SF3B1 are exemplary spli-
ceosomal proteins found in a complex with DDX41. Western
blotting of native protein in primary extract as well as immuno-
precipitates obtained with anti-DDX41 confirmed the findings
of the mass spectrometry experiments (Figure S6C). Of note,
mutations in DDX41 (R525H) altered the native DDX41 interac-
tome especially for major components in U2 (SF3B1, SF3B2,
and SF3B3) and U5 (PRPF8 and SNRNP200) spliceosomes (Fig-
ure 5B). Western blots performed for SF3B1 and PRPF8 (Fig-
ure S6D) confirmed the differences between mutant and WT
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DDX41 immunoprecipitates. Notably, our analyses showed that
these protein-protein associations persisted after nuclease
digestion of RNA.
To investigate the possible impact of defective DDX41 on pre-
mRNA splicing, deepwhole RNA sequencing was investigated in
deletion, mutant, and WT cases (Przychodzen et al., 2013). The
analysis involved 148,318 exons and comparison of their
average usages between DDX41 defects (n = 5) and controls
(n = 11) (Figure 6A; Figure S7A). DDX41 defects were associated
with more avid exon skipping (excess of shorter mRNA missing
an exon) andmore exon retention (excess of longer mRNA incor-
porating an exon) in 61 and 95 genes, respectively. The top ten
most differentially misspliced exons (Figure 6B; top 40 gene
list in Table S6) in functionally important genes were examined
by RT-PCR. The difference of skipping ratio in ZMYM2 exon 3
can be used as an illustrative example (13% difference
between DDX41 defect and WT; p = 0.019) (Figure 6C). The
enhanced skipping of this exon, located in the 50UTR was
recapitulated by DDX41 knockdown in K562 and CD34+ cells.
In contrast, overexpression of WT DDX41 in U937 cells led to
decreased exon skipping of ZMYM2 in comparison to mock
transduction (Figure 6D; Figures S7B and S7C). In addition to
the changes in spliced isoform ratios, ZMYM2 mRNA was
expressed at significantly lower levels in DDX41 low expressors
(p < 0.001; Figure S7D). ZMYM2 encodes a zinc finger protein
involved in a histone deacetylase complex (Bantscheff et al.,
2011) and may constitute one of the downstream elements
associated with DDX41 defects via its interaction with the
LSD1-CoREST-HDAC1 co-repressor complex (Gocke and Yu,
2008). This complex is activated in various cancers and downre-
gulates transcription of tumor suppressor genes. When we
analyzed RNA expression patterns (Boultwood et al., 2007),
low ZMYM2 mRNA levels were associated with down-modula-
tion of SMC3, RAD21, and RUNX1, which were also significantly
under-expressed in cases with low DDX41 (Figure S7E).
DISCUSSION
Several familial leukemia syndromes have been identified (Owen
et al., 2008; Hahn et al., 2011; Liew and Owen, 2011). However,
the incomplete penetrance and the increased frequency of
myeloid disorders at older age may have hindered the identifica-
tion of more inherited leukemia syndromes in older adults.
Germline DDX41 lesions define a hereditary MDS/AML syn-
drome that is characterized by long latency, advanced disease
(high-risk MDS/AML), normal karyotype, and poor prognosis.
Germline variants of DDX41may convey a strong predisposition
to MDS and subsequent AML and are likely to serve as a ‘‘first
hit,’’ or an ancestral event. The canonical frameshift insertion in
DDX41might be more frequent than previously described germ-
line RUNX1, CEBPA, and GATA2 defects (Owen et al., 2008;
Hahn et al., 2011).
In addition to germline DDX41 mutation, we report here in
myeloid neoplasms canonical somatic mutations in this gene,
often coinciding as a second hit with the germline mutations.
By all the established and recognized criteria (Lawrence et al.,
2014), somatic DDX41 mutations we found are driver mutations
(Makishima et al., 2014). Of note is that a somatic splice-site
DDX41 mutation was previously listed along with other somatic
mutations found in The Cancer Genome Atlas (TCGA) (Ding
et al., 2012; The Cancer Genome Atlas Research Network,
2013); TCGA cohort also contained the recurrent p.R525H
mutation. However, the aforementioned studies did not further
investigate somatic DDX41mutations. The association between
somatic and germline variants had not been elucidated. The
frequency of the leukemogenic allele of DDX41 in the general
population is very low, and because of late presentation, some
healthy carriers may still anticipate disease. Mild abnormalities
can be noted on careful evaluation of asymptomatic carriers.
The germline DDX41 lesions strongly predispose to further
somatic hits in the remaining healthy allele of this gene, sug-
gesting that a higher level of haploinsufficiency created by a
somatic missense mutation further enhances the clonal advan-
tage. However, carriers of the inactivating variant germline
c.419insGATG acquire somatic hypomorphic rather than inacti-
vating mutations. Thus, total (biallelic) inactivation of the gene
does not seem to be permissive, as we did not find any cases
of germline DDX41 mutations followed by somatic deletion of
its healthy allele.
The pro-leukemogenic properties of DDX41 lesions are sup-
ported by the presence of somatic mutations in this gene and
the consistent lack of pathognomonic AML lesions, such as
typical cytogenetic abnormalities or primary AML-specific muta-
tions. Germline alterations may constitute a predisposition factor
for the acquisition of somatic mutations in the same genes, as is
the case with JAK2, in which the rs10974944 polymorphism in-
creases the risk for somatic JAK2 V617F mutations (Kilpivaara
et al., 2009; Olcaydu et al., 2009). Similar to CEBPA and RUNX1
mutations, biallelic DDX41 mutations occur in germline DDX41
frameshift mutations carriers as secondary somatic mutations.
Notably, similar to the somatic CEBPA mutations, the somatic
DDX41mutationsarehypomorphic, but thepenetranceofCEBPA
mutations is high, whereas it is currently unknown for DDX41. In-
dex family 1had four affectedmembers inclear succession.Since
the father did not develop disease until the age of 70, it is unclear
whether all affected individualswill eventually developMDS/AML.
The long latency is also supported by the finding of the germline
mutation in adult carrier family members who did not so far
develop leukemia. However, they were younger than most of
the patients with germline DDX41 mutations. In contrast to the
RUNX1/CEBPAmutations (Owen et al., 2008), DDX41mutations
induce disease at age >40 years. In germline GATA2 mutations
carriers, only 16%remain asymptomatic by the ageof 40 (Spinner
et al., 2014). In our cohort, we found both germline and somatic
mutations ofDDX41. Germlinemutations in familial leukemia syn-
dromes and somatic mutations of the same gene in sporadic
cases are a hallmark of key drivers in leukemogenesis such as
CEBPA.
Similar to previously described spliceosomalmutations (Yosh-
ida et al., 2011; Makishima et al., 2012), the precise mechanisms
by which DDX41 lesions exert their pro-leukemogenic defects
are unclear. A recent report on comprehensive gene expression
and mutational profiles in medulloblastoma also showed
frequently lower expression levels of DDX41 and frequent muta-
tions of another RNA helicase DDX3X, which suggests that
defective helicase functions might be related to common mech-
anisms for tumorigenesis (Kool et al., 2014). The physiological
role of spliceosomal proteins is well characterized, but the
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Figure 6. Deep Whole RNA-Seq Showed Splicing Defects in DDX41-Deficient Cells
(A) Increased exon skipping (top) and retention (bottom) in patients withDDX41 defects are indicated by an excess of green reads and red reads, respectively. The
center panel shows a scatterplot of exon skipping in RNA isolated from control cells versus RNA from DDX41-defective mutant cells. Lines show the 10%
difference cutoff limit used to select the most frequently affected exons.
(B) Deep RNA sequencing was performed for blasts from patients with DDX41mutations, deletions, and wild-type to analyze altered splicing. The bar diagrams
indicate the top ten genes significantly more skipped inDDX41 defects (top) and in DDX41WT (bottom). The arrow indicates the 13% difference of exon skipping
in the ZMYM2 gene when comparing DDX41 defect and WT samples.
(C) Exon 3 of ZMYM2 was skipped in DDX41-deficient cells as demonstrated by the read counts from deep sequencing.
(D) RT-PCR was performed in K562 cells, CD34+ progenitors, and U937 cells to evaluate ZMYM2 exon 3 skipping compared with controls. Depicted is the
skip:retain intensity ratio for WT and DDX41 knockdown/overexpressing samples. Each bar represents the mean ± SEM of three independent experiments.
See also Figure S7 and Table S6.
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functions of RNA helicases are far less well defined and might
include a possible involvement in spliceosomal function, ribo-
some biogenesis, and translation initiation (Putnam and Jankow-
sky, 2013). Both somatic and germline mutations indicate that
DDX41 is a tumor suppressor gene and an important driver in
myeloid malignancies. To that end DDX41 is exemplary of other
DEAD/H-box helicases that are also mutated in myeloid neo-
plasms. It is possible that RNA helicase mutations constitute a
separate class of spliceosomal defects. Spliceosomal mutations
induce splicing dysfunction (Przychodzen et al., 2013; Makish-
ima et al., 2012), and our results indicate that DDX41 mutations
also result in a specific missplicing pattern and altered expres-
sion of specific downstream genes.
DDX41 defects lead to a hereditary leukemia syndrome, and
somatic lesions of this gene also occur in sporadic myeloid neo-
plasms. A significant proportion of del(5q) cases include the
DDX41 locus, which leads to haploinsufficiency in a sizable pro-
portion of patients with myeloid neoplasms. It is possible that
DDX41 plays a role in the pathogenesis of del(5q), in particular
in those cases with longer interstitial deletions, which, unlike
the smaller defects, convey unfavorable prognosis (Jerez et al.,
2012). Indeed, DDX41 defects were associated with advanced
disease and poor prognosis.
The presence of DDX41 mutations or deletions was associ-
ated with responsiveness to lenalidomide. This finding might
constitute a possible therapeutic intervention for otherwise
poor risk disease, but further studies are necessary to determine
the predictive value of DDX41 mutations, deletions, or low
expression for lenalidomide response.
Recent reports suggest the existence of pre-leukemic stem
cells in MDS (Woll et al., 2014) and in AML (Shlush et al.,
2014). These pre-leukemic stem cells contain a first hit that
significantly enhances the likelihood of subsequent leukemia
development. The germline DDX41 mutations induce MDS/
leukemia with long latency but significant penetrance. Thus,
DDX41 lesions might genuinely induce a pre-leukemic state
that predisposes for leukemia.
In summary, we identified germline mutations in DDX41 that
are associated with the development of hereditary MDS and
AML. The strong family history and late onset suggest high pene-
trance with long disease latency. Germline DDX41 defects
strongly predispose to somatic DDX41 mutations.
EXPERIMENTAL PROCEDURES
Patients’ Samples
Bone marrow aspirates or blood samples were collected from the eight index
cases (families 1–4); an additional 840 patients with myeloid neoplasms seen
at Cleveland Clinic, University of Muenster, and University of Chicago; and 197
cases from TCGA database (n = 1,045; Table S1). Informed consent for sample
collection was obtained according to protocols approved by the institutional
review boards (Cleveland Clinic, Ethik-Kommission der A¨rztekammer
Westfalen-Lippe und der medizinischen Fakulta¨t der Westfa¨lischen Wilhelms
Universita¨t Mu¨nster, and University of Chicago) and in accordance with the
Declaration of Helsinki. Diagnosis was confirmed according to 2008 WHO
classification criteria. Tumor DNAswere extracted from patients’ bonemarrow
cells. For germline controls, DNA was obtained from paired CD3+ T cells or
buccal swab. Index patients from family 1 were analyzed at diagnosis (and
relapse). First complete remission samples were additionally used as surro-
gate for germline DNA. Germline DDX41 mutation was confirmed by Sanger
sequencing in buccal swab DNA in index patients case 2 and case 3.
NGS Studies
WES was performed as previously described (Yoshida et al., 2011). To detect
allelic frequencies for mutations or SNPs, we applied deep next-generation
multi-amplicon sequencing to targeted exons (Yoshida et al., 2011). The
multi-amplicon panel included 62 genes. Libraries were generated according
to standard procedures and paired-end sequenced (see Supplemental Exper-
imental Procedures).
Cytogenetics and SNP Arrays
Technical details regarding sample procession for SNP array assays were pre-
viously described (Maciejewski et al., 2009; Gondek et al., 2008). The Gene
Chip Mapping 250K Assay kit and the Genome-Wide Human SNP Array 6.0
(Affymetrix) were used. A stringent algorithm was applied for the identification
of lesions using SNP arrays. Individuals with lesions identified by SNP array
concordant with those identified in metaphase cytogenetics or typical lesions
known to be recurrent required no further analysis. Changes reported in our in-
ternal or publicly available (Database of Genomic Variants; http://dgv.tcag.ca/
dgv/app/home) copy number variation (CNV) databaseswere considered non-
somatic and were excluded. Results were analyzed using CNAG (v3.0)
(Nannya et al., 2005) or Genotyping Console (Affymetrix). All other lesions
were confirmed as somatic or germline by analysis of CD3-sorted cells (Tiu
et al., 2009).
qRT-PCR with TaqMan Probes
Total RNA was extracted from bone marrow mononuclear cells and cell lines.
cDNA was synthesized from 500 ng total RNA using the SuperScript III
First-Strand Synthesis System (Invitrogen). Quantitative gene expression
levels were detected using real-time PCR with the ABI PRISM 7500 Fast
Sequence Detection System and FAM dye labeled TaqMan MGB probes
(Applied Biosystems). TaqMan assays were performed according to the man-
ufacturer’s instructions. Primers and probes for all genes analyzed were pur-
chased from Applied Biosystems gene expression assays products (DDX41:
Hs00169602_m1; and GAPDH: Hs99999905_m1). The expression level of
target genes was normalized to the GAPDH mRNA.
Whole RNA-Seq
We used publicly available RNA-seq data from TCGA data portal for 97 pa-
tients (https://tcga-data.nci.nih.gov/tcga). We selected three cases that
showed deletion of 5q, including DDX41 locus; one case harbored DDX41mu-
tation (c.G1574A, p.R525H); and one case showed low expression of DDX41,
for which deep RNA-seq (Tarazona et al., 2011) data were available. We also
selected 11 cases that were WT for any spliceosomal factor mutation (see
Supplemental Experimental Procedures).
Cell Culture, Lentiviral-Mediated shRNA Knockdown, and Lentiviral
Expression Vector
HL60 (human promyelocytic cell line), U937 (human monocytic cell line), and
K562 (human chronic myelocytic leukemia cell line) cells were cultured using
Iscove’s Modified Dulbecco’s Medium + 10% fetal bovine serum (FBS). The
pLKO.1_DDX41-shRNA and the control non-target shRNA were purchased
from Sigma-Aldrich. In brief, 293T cells were transfected with shRNA target-
ing DDX41 or non-target shRNA control plasmid together with packing
plasmid pCMVD8.2 and envelope plasmid containing VSV-G. Viral superna-
tants were harvested at 48, 72, and 96 hr posttransfection, and target cells
were infected in the presence of 8 mg/ml polybrene for 24 hr and selected
with puromycin (2 mg/ml for K562 and 1 mg/ml for HL60). For CD34+ primary
cells, we used 25 mg/ml of Retronectin instead of polybrene. Lentiviral
expression vector (pLX304, clone ID: HsCD00442077; DNASU Plasmid Re-
pository) was used to generate viral supernatants. U937 was transfected in
the presence of 8 mg/ml polybrene for 24 hr, and then selected with blastici-
din (5 mg/ml).
Human CD34+ Colony Assays
CD34+ cells were isolated from healthy bone marrow. Informed consent for
sample collection was obtained according to the protocols and procedures
approved by the Cleveland Clinic Foundation (CCF) institutional review board
(IRB3952 and IRB5024) and in accordance with the Declaration of Helsinki.
Approximately 5 3 104 sorted human CD34+ cells from healthy donors were
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plated on methylcellulose according to the MethoCult technical manual
(H4230; StemCell Technologies). Lentivirally infected human CD34+ cells
were added to methylcellulose medium supplemented with 10 ng/ml human
IL-3, 50 ng/ml SCF, 3 U/ml erythropoietin, 10 ng/ml GM-CSF, and 20% FBS.
The number of burst-forming units-erythroid (BFU-E) and colony-forming units
granulocyte-macrophage (CFU-GM) was accessed after 10- to 14-day culture
at 37C in humidified atmosphere with 5% CO2, as per the manufacturer’s in-
structions. For the assessment of sensitivity to stimuli, both DDX41-deficient
and control CD34+ cells were plated in various amounts of granulocyte-macro-
phage colony-stimulating factor (GM-CSF) (0, 1, and 10 ng/ml of GM-CSF) and
FBS (0%, 10%, 20%, and 30% of FBS). Colonies were evaluated after 10- to
14-day culture. For serial methylcellulose replating assay, CD34+ cells were
plated on methylcellulose with cytokines. After 10 to 14 days, the colony
numbers were counted under microscope. The colonies were picked up,
and cells were pooled and replated (104 cells/plate) onto secondarymethylcel-
lulose plates. Three rounds of replating were performed for each experiment
(Sontakke et al., 2014; He et al., 2011).
In Vivo Tumor Xenograft
Tumor xenograft studies were performed in accordance with recommenda-
tions in Guide for the Care and Use of Laboratory Animals of the NIH and
were conducted under a protocol approved by Cleveland Clinic Institutional
Animal Care and Use Committee. K562 cell line was transfected with lentivi-
ruses carrying control shRNA, or DDX41-targeting shRNA. A total of 10 3
106 cells were diluted in PBS 100 ml and injected subcutaneously into the flank
of 8-week-old NOD scid gamma mice (NSG) mice. Mock cells were injected in
the right flank, while sh-DDX41 cells were injected in the left flank. Tumor vol-
umes were measured in two dimensions (length and width) using a dial caliper
and were calculated using the following formula: tumor volume = (length 3
width2)3 0.5. Tumor volume was measured every 7 days. Three independent
experiments were performed in triplicate.
Immunoprecipitation
V5 immunoprecipitation was performed with V5-tagged WT and mutant
DDX41 (R525H) in HEK293 cells. Nuclear protein extracts (10 mg of protein)
were transferred to tubes with antibody-bound protein G beads and rocked
gently at 4C overnight. Nonspecifically bound proteins were removed with
five washes of PBS containing 1% Nonidet P-40. Immunoprecipitation
products were extracted from protein G beads using Laemmli sample buffer.
Immunoprecipitates were analyzed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Peak-intensity-based label-free comparison was
employed to compare relative protein abundance.
Statistical Analysis
The Kaplan-Meier method was used to analyze OS by the log-rank test. Pair-
wise comparisons were performed by Wilcoxon test for continuous variables
and by two-sided Fisher’s exact test for categorical variables. For multivariate
analyses, a Cox proportional hazards model was employed. Variables consid-
ered for model inclusion were International Prognostic Scoring System (IPSS)
risk group, age, sex, and gene mutation status. The statistical significance of
functional studies was evaluated using a two-tailed t test. Significance was
determined at a two-sided a level of 0.05, except for p values in multiple com-
parisons, in which Bonferroni correction was applied.
ACCESSION NUMBERS
WES results have been deposited in the Sequence Read Archive (SRA;
BioProject accession number: PRJNA275985). The GEO accession number
for SNP Arrays is GSE66668.
SUPPLEMENTAL INFORMATION
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